SK13892002A3 - Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu - Google Patents
Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu Download PDFInfo
- Publication number
- SK13892002A3 SK13892002A3 SK1389-2002A SK13892002A SK13892002A3 SK 13892002 A3 SK13892002 A3 SK 13892002A3 SK 13892002 A SK13892002 A SK 13892002A SK 13892002 A3 SK13892002 A3 SK 13892002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- tyr
- ser
- gly
- binding molecule
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007911.1A GB0007911D0 (en) | 2000-03-30 | 2000-03-30 | Organic compounds |
| PCT/EP2001/003541 WO2001072845A1 (en) | 2000-03-30 | 2001-03-28 | Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK13892002A3 true SK13892002A3 (sk) | 2003-05-02 |
Family
ID=9888901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1389-2002A SK13892002A3 (sk) | 2000-03-30 | 2001-03-28 | Molekula viažuca CD25 na použitie na liečenie zápalových ochorení gastrointestinálneho traktu |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20050226872A1 (https=) |
| EP (1) | EP1268553A1 (https=) |
| JP (1) | JP2003528890A (https=) |
| KR (2) | KR20080079702A (https=) |
| CN (1) | CN1416432A (https=) |
| AU (2) | AU4651601A (https=) |
| BR (1) | BR0109549A (https=) |
| CA (1) | CA2401249A1 (https=) |
| GB (1) | GB0007911D0 (https=) |
| HU (1) | HUP0301846A3 (https=) |
| IL (1) | IL151089A0 (https=) |
| NO (1) | NO20024579L (https=) |
| NZ (1) | NZ520547A (https=) |
| PL (1) | PL357014A1 (https=) |
| RU (1) | RU2286797C2 (https=) |
| SK (1) | SK13892002A3 (https=) |
| WO (1) | WO2001072845A1 (https=) |
| ZA (1) | ZA200207736B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2443405A1 (en) * | 2001-04-06 | 2002-10-17 | University Of Bristol | Use of cd25 binding molecules in steroid-resistant patients |
| EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| EP2387711B1 (en) * | 2009-01-15 | 2015-04-22 | Laboratory Corporation of America Holdings | Methods of determining patient response by measurement of her-3 |
| JP2012515353A (ja) * | 2009-01-15 | 2012-07-05 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | Ｈｅｒ−２発現の測定による患者の反応を判定する方法 |
| RU2500427C2 (ru) * | 2010-07-15 | 2013-12-10 | Олег Ильич Эпштейн | Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта |
| MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT60768A (en) * | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
| JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| DE69937057T2 (de) * | 1998-07-27 | 2008-05-29 | Novartis Ag | Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen |
-
2000
- 2000-03-30 GB GBGB0007911.1A patent/GB0007911D0/en not_active Ceased
-
2001
- 2001-03-28 PL PL01357014A patent/PL357014A1/xx unknown
- 2001-03-28 KR KR1020087020504A patent/KR20080079702A/ko not_active Ceased
- 2001-03-28 EP EP01919404A patent/EP1268553A1/en not_active Withdrawn
- 2001-03-28 AU AU4651601A patent/AU4651601A/xx active Pending
- 2001-03-28 HU HU0301846A patent/HUP0301846A3/hu unknown
- 2001-03-28 NZ NZ520547A patent/NZ520547A/en unknown
- 2001-03-28 WO PCT/EP2001/003541 patent/WO2001072845A1/en not_active Ceased
- 2001-03-28 SK SK1389-2002A patent/SK13892002A3/sk not_active Application Discontinuation
- 2001-03-28 BR BR0109549-8A patent/BR0109549A/pt not_active IP Right Cessation
- 2001-03-28 IL IL15108901A patent/IL151089A0/xx unknown
- 2001-03-28 US US10/240,353 patent/US20050226872A1/en not_active Abandoned
- 2001-03-28 KR KR1020027009850A patent/KR20020084107A/ko not_active Ceased
- 2001-03-28 RU RU2002127800/15A patent/RU2286797C2/ru active
- 2001-03-28 AU AU2001246516A patent/AU2001246516B2/en not_active Ceased
- 2001-03-28 CA CA002401249A patent/CA2401249A1/en not_active Abandoned
- 2001-03-28 CN CN01806231A patent/CN1416432A/zh active Pending
- 2001-03-28 JP JP2001571776A patent/JP2003528890A/ja active Pending
-
2002
- 2002-09-24 NO NO20024579A patent/NO20024579L/no unknown
- 2002-09-26 ZA ZA200207736A patent/ZA200207736B/en unknown
-
2008
- 2008-02-29 US US12/074,083 patent/US20090041775A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0301846A2 (hu) | 2003-09-29 |
| BR0109549A (pt) | 2003-06-10 |
| KR20020084107A (ko) | 2002-11-04 |
| AU2001246516B2 (en) | 2005-06-30 |
| CA2401249A1 (en) | 2001-10-04 |
| NZ520547A (en) | 2005-04-29 |
| PL357014A1 (en) | 2004-07-12 |
| ZA200207736B (en) | 2003-05-08 |
| NO20024579L (no) | 2002-11-11 |
| IL151089A0 (en) | 2003-04-10 |
| CN1416432A (zh) | 2003-05-07 |
| US20050226872A1 (en) | 2005-10-13 |
| RU2002127800A (ru) | 2004-03-27 |
| US20090041775A1 (en) | 2009-02-12 |
| KR20080079702A (ko) | 2008-09-01 |
| GB0007911D0 (en) | 2000-05-17 |
| JP2003528890A (ja) | 2003-09-30 |
| RU2286797C2 (ru) | 2006-11-10 |
| WO2001072845A1 (en) | 2001-10-04 |
| NO20024579D0 (no) | 2002-09-24 |
| HUP0301846A3 (en) | 2010-07-28 |
| EP1268553A1 (en) | 2003-01-02 |
| AU4651601A (en) | 2001-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090041775A1 (en) | Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract | |
| JP6875363B2 (ja) | 神経変性障害の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| RU2540018C2 (ru) | Средство для лечения заболевания | |
| EP0939652B1 (en) | Use of antibodies to cd45ro leukocyte antigen for immunomodulation | |
| JP6694269B2 (ja) | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 | |
| TW200815468A (en) | Use of organic compounds | |
| CN104402999A (zh) | Trail受体结合剂和其用途 | |
| ZA200308999B (en) | Anti ngf antibodies for the treatment of various disorders | |
| TW201902514A (zh) | Ｐｄ－１抗體與ｖｅｇｆ配體或ｖｅｇｆ受體抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| AU748533B2 (en) | Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses | |
| RS65652B1 (sr) | Postupci lečenja bolesti u kojima je dejstvo il-13 štetno pomoću antitela protiv il-13 | |
| AU2003303339A1 (en) | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents | |
| CN101657215A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| AU2001246516A1 (en) | Use of CD25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract | |
| JP2003528890A5 (https=) | ||
| PT1737490E (pt) | Processos de tratamento da aterosclerose | |
| IL322211A (en) | Methods and preparations for combined therapy | |
| EP1100829B1 (en) | Use of basiliximab in the treatment of rheumatoid arthritis or skin diseases | |
| CZ20032672A3 (cs) | CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy | |
| CN112439060B (zh) | Pd-l1免疫疗法的新用途 | |
| EA051900B1 (ru) | Антитела против cd112r и варианты их применения | |
| WO2021038097A1 (en) | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells | |
| BRPI0720924A2 (pt) | Métodos de tratamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |